Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IZTC NASDAQ:KRRO NASDAQ:SGMT NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIZTCInvizyne Technologies$11.96+13.1%$9.84$8.50▼$23.00$74.77MN/A37,647 shs7,095 shsKRROKorro Bio$33.18+18.2%$17.18$10.29▼$98.00$311.59M2.66168,762 shs1.01 million shsSGMTSagimet Biosciences$7.11-1.9%$8.53$1.73▼$11.41$231.23M3.34582,299 shs381,820 shsTNXPTonix Pharmaceuticals$26.54+0.9%$40.55$6.76▼$130.00$232.65M1.861.85 million shs1.36 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIZTCInvizyne Technologies+13.10%+23.30%+19.48%-10.98%+1,195,999,900.00%KRROKorro Bio0.00%+43.76%+109.21%+127.42%-21.76%SGMTSagimet Biosciences0.00%-5.33%-21.44%+27.88%+146.88%TNXPTonix Pharmaceuticals0.00%-10.43%-43.44%-34.71%+61.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIZTCInvizyne Technologies$11.96+13.1%$9.84$8.50▼$23.00$74.77MN/A37,647 shs7,095 shsKRROKorro Bio$33.18+18.2%$17.18$10.29▼$98.00$311.59M2.66168,762 shs1.01 million shsSGMTSagimet Biosciences$7.11-1.9%$8.53$1.73▼$11.41$231.23M3.34582,299 shs381,820 shsTNXPTonix Pharmaceuticals$26.54+0.9%$40.55$6.76▼$130.00$232.65M1.861.85 million shs1.36 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIZTCInvizyne Technologies+13.10%+23.30%+19.48%-10.98%+1,195,999,900.00%KRROKorro Bio0.00%+43.76%+109.21%+127.42%-21.76%SGMTSagimet Biosciences0.00%-5.33%-21.44%+27.88%+146.88%TNXPTonix Pharmaceuticals0.00%-10.43%-43.44%-34.71%+61.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIZTCInvizyne Technologies 0.00N/AN/AN/AKRROKorro Bio 3.29Buy$86.83161.70% UpsideSGMTSagimet Biosciences 3.00Buy$25.67260.99% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.00163.75% UpsideCurrent Analyst Ratings BreakdownLatest IZTC, KRRO, TNXP, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $90.008/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$29.007/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.007/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.006/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $27.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AKRROKorro Bio$2.27M137.25N/AN/A$17.12 per share1.94SGMTSagimet BiosciencesN/AN/AN/AN/A$5.08 per shareN/ATNXPTonix Pharmaceuticals$10.09M23.07N/AN/A$31.82 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AKRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%11/13/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)Latest IZTC, KRRO, TNXP, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/A8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIZTCInvizyne TechnologiesN/AN/AN/AKRROKorro BioN/A5.985.98SGMTSagimet BiosciencesN/A17.5517.55TNXPTonix PharmaceuticalsN/A7.537.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIZTCInvizyne TechnologiesN/AKRROKorro Bio13.18%SGMTSagimet Biosciences87.86%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipIZTCInvizyne TechnologiesN/AKRROKorro Bio4.60%SGMTSagimet Biosciences14.70%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIZTCInvizyne Technologies296.25 millionN/AN/AKRROKorro Bio709.39 million8.96 millionNo DataSGMTSagimet Biosciences832.52 million27.74 millionOptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableIZTC, KRRO, TNXP, and SGMT HeadlinesRecent News About These CompaniesThree new option listings and one option delisting on September 4thSeptember 4 at 5:03 PM | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Should You Sell?September 4 at 3:13 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Here's WhySeptember 3, 2025 | americanbankingnews.comTonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025August 28, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Time to Sell?August 28, 2025 | marketbeat.comCarolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) StockAugust 22, 2025 | insidertrades.comSA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXPAugust 20, 2025 | msn.comTonix Pharma Announces FDA Approval of TonmyaAugust 19, 2025 | msn.comTonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)August 19, 2025 | seekingalpha.comTonix Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comFDA Approves New Fibromyalgia Drug, But Tonix Shares SlideAugust 18, 2025 | msn.comTonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 YearsAugust 18, 2025 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA ApprovalAugust 18, 2025 | gurufocus.comFDA Approves New Fibromyalgia Drug, Tonix Shares ClimbAugust 18, 2025 | msn.comThis Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’August 18, 2025 | msn.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLCAugust 18, 2025 | marketbeat.comNoble Financial Has Pessimistic Outlook of TNXP Q3 EarningsAugust 17, 2025 | marketbeat.comFDA approves first new fibromyalgia treatment in over 15 yearsAugust 16, 2025 | thepharmaletter.comTTonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comTonix Secures Fibromyalgia Approval - What Investors Should KnowAugust 16, 2025 | seekingalpha.comTonix Pharma Gains FDA Approval for TonmyaAugust 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, KRRO, TNXP, and SGMT Company DescriptionsInvizyne Technologies NASDAQ:IZTC$11.96 +1.39 (+13.10%) As of 09/5/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Korro Bio NASDAQ:KRRO$33.18 +5.10 (+18.16%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$33.12 -0.05 (-0.17%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Sagimet Biosciences NASDAQ:SGMT$7.11 -0.14 (-1.93%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.10 -0.01 (-0.14%) As of 09/5/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Tonix Pharmaceuticals NASDAQ:TNXP$26.54 +0.23 (+0.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$26.46 -0.09 (-0.32%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
